secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vigil Neuroscience, Inc. (—)
CIK:        0001827087
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001193125-24-133141
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vigil Neuroscience reports Q1 net loss $19.9M; completes enrollment for Phase 2 ALSP trial, data in Q3 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents & marketable securities $101.6M as of Mar 31, 2024; expected to fund operations into H2 2025.
- Completed enrollment for Phase 2 IGNITE trial of iluzanebart in ALSP with 20 patients, exceeding planned 15.
- Next data readout from Phase 2 IGNITE planned for Q3 2024, including 12-month data from 20 mg/kg cohort and 6-month from 40 mg/kg.
- Phase 1 trial of VG-3927 for Alzheimer's ongoing; interim healthy volunteer data expected mid-2024.
- Appointed Petra Kaufmann as Chief Medical Officer; she brings over 25 years of neurology drug development experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/0001193125-24-133141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/d825217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer